NWRD06 not checked

Newish Technology (Beijing) Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“DNA plasmid delivered via IM injection + electroporation using TERESA device”In the company’s words, NCT07324304 on ClinicalTrials.gov
Tested for
Hepatocellular Carcinoma (HCC)
Main trialPhase 2
“This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.”In the company’s words, NCT07324304 on ClinicalTrials.gov

Other drugs for Hepatocellular Carcinoma (HCC)

All 130 drugs for Hepatocellular Carcinoma (HCC)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Dec 2028 NWRD06 DNA Plasmid for HCC After Curative Resection.
Phase 1Unknown Dec 2024 NWRD06 DNA Plasmid for HCC After Radical Resection
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow NWRD06

Following is part of Solo: you see every change to NWRD06 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in